01 · The promise
EuroFlow panels · the capability of a €350k–€500k spectral cytometer · on a ~€6.0k reader
The immunophenotyping capability of a spectral cytometer,
on a ~€6.0k single-use reader.
A single-use silicon-photonics chip runs your EuroFlow workload on a benchtop reader — at a fraction of the reagent load and no service contract. We're proving it against labs' own panels right now. See what it could recover on yours, then help us put real concordance data behind it.
Your numbers, right nowplanning estimate
€187k
Recoverable per site, per year
under a month
Reader payback
€562k
Across 3 sites
Research use today; CE-IVD roadmap 2028 (UKCA self-certification 2027). Every figure is validated on your own samples during the pilot — not a clinical or regulatory claim.
We won't show you a concordance plot we haven't earned. Here's exactly where the evidence stands.
See it as the budget case, or the bench case.
02 · Your numbers
Your workload
Start from a lab like yours, then fine-tune.
SITES
3 sites
4 panels · 3 sites · Typical hematology lab
The budget case · 3 sites
planning estimate€187k
Recoverable per site, per year
under a month
Reader payback
€562k
Across 3 sites
Reader replaces the incumbent at this site?
Off by default — we count reagent + consumables only and keep your Cytek/BD in place. Turn it on only if the reader retires that instrument, which adds the service-contract saving to the case.
The mechanism · per case: your tubes vs one chip
The auditable line — what a single case costs today against the reader.
AML / MDS
7 tubes · 1/day/site
Current€321
Reader€45
€276
saved / case
B-CLPD
5 tubes · 1/day/site
Current€231
Reader€45
€186
saved / case
LST
1 tube · 4/day/site
Current€51
Reader€10
€41
saved / case
+ 1 more panel in the full breakdown below.
How firm is each euro? · per site / year
Defensible today
€0 until you confirm displacement above. Even so: ~€6.0k vs €350k–€500k capital per reader, same method.
In validation (reagent-real)
Deep panels — your multi-tube AML/MDS and classification reagent load vs one chip. Doesn't touch your screening method. In validation on labs' own samples now.
Aspirational (flagged upside)
Reagent-free screening via AI virtual staining — in validation. Zero this line out and the case above still stands on its own.
Why this is conservative
Chips are priced at the complex-panel end, deep panels keep a residual reagent load, labour is off, and the service saving stays off until you confirm the reader retires your incumbent. The reagent lines on the deep panels carry the case without touching your screening method — tighten anything in Assumptions.What stays the same
We replace the flow-cytometry screening and classification step, not the workflow. No serology, molecular (PCR/NGS/ctDNA), cytogenetics (karyotype/FISH), mass spec, or histology — and deep-sensitivity EuroFlow MRD stays on your reference analyser. Those aren't in these numbers.03 · Partner
Become a design partner
Prove it on your own residual samples
We're taking a small first cohort of European haematology labs — partner pricing locked, priority on validating your panels, and co-authorship on the EuroFlow comparison. The first step is a blinded side-by-side on your own leftover samples, not a purchase.
What a pilot costs you
No capital outlay — we place the reader. You run your own residual samples in parallel on your own instrument. Research / parallel use only: no clinical reporting, outside your ISO 15189 scope, so it creates no nonconformity — and we supply the validation protocol. You keep the data, and walk away anytime.Where the evidence stands. What we've shown so far: label-free leukocyte differentiation (Yoon et al., 2017) and CTC morphology (APL Bioengineering, 2023). What this cohort builds: the EuroFlow concordance dataset that doesn't exist yet. Scientific advisory being announced with the founding cohort.
We use your details only to follow up on this. Your savings inputs travel with the request so the first conversation is about your numbers.